GeNeuro, Servier Aim To Develop First Drug Addressing Causal MS Factor
This article was originally published in The Pink Sheet Daily
Executive Summary
Servier of France will progress Swiss biotech GeNeuro’s monoclonal antibody through Phase III trials aimed at the MSRV-Env protein which, if successful, could transform how multiple sclerosis is treated.